Skip to main content

Submitting Claims for Some HCCAD Procedure Codes

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.

Effective for dates of service on or after June 1, 2025, Texas Medicaid may reimburse hospital claims for some high-cost clinician-administered drug (HCCAD) procedure codes separately from the diagnosis-related group (DRG) reimbursement.

The following HCCAD procedure codes may be reimbursed separately:

Drug NameProcedure Code
AbecmaQ2055
BreyanziQ2054
CarvyktiQ2056
CasgevyJ3392
ElevidysJ1413
HemgenixJ1411
KymriahQ2042
LyfgeniaJ3394
RoctavianJ1412
TecartusQ2053
TecelraQ2057
YescartaQ2041
ZolgensmaJ3399
ZyntegloJ3393

To request reimbursement for one of these drugs, hospital providers must submit an outpatient claim with the appropriate procedure code and national drug code (NDC) to the Texas Medicaid & Healthcare Partnership (TMHP).

Claims for Skysona (Procedure Code J3590)

Texas Medicaid will begin to separately reimburse claims for Skysona (procedure code J3590) on December 12, 2025, for dates of service on or after June 1, 2025. Providers must submit outpatient claims for Skysona with the U3 modifier and the NDC.

TMHP will provide more information about Skysona in a future notification on tmhp.com.

Important: Providers must request prior authorization for HCCADs. Refer to the Outpatient Drug Services Handbook in the Texas Medicaid Provider Procedures Manual (TMPPM).

For more information, call the TMHP Contact Center at 800-925-9126.